Literature DB >> 17629615

Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT.

Christina Westmose Yde1, Thomas Frogne, Anne E Lykkesfeldt, Iduna Fichtner, Olaf-Georg Issinger, Jan Stenvang.   

Abstract

Protein kinase CK2 is involved in cell proliferation and survival, and found overexpressed in virtually all types of human cancer, including breast cancer. We demonstrate that inhibition of CK2 with 2-dimethylamino-4,5,6,7-tetrabromo-benzimidazole (DMAT), a potent and specific CK2 inhibitor, results in caspase-mediated killing of human breast cancer cells with acquired resistance to antiestrogens, while DMAT fails to kill parental MCF-7 cells. The antiestrogen resistant breast cancer cells express reduced levels of Bcl-2 compared to MCF-7 cells. Reduced Bcl-2 protein level is also found in a tamoxifen resistant human breast tumor grown as a xenograft. We show that re-expression of Bcl-2 partially rescues antiestrogen resistant MCF-7 sublines from DMAT-induced cell death. In summary, our data suggest a novel role of CK2 in antiestrogen resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17629615     DOI: 10.1016/j.canlet.2007.06.010

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  18 in total

1.  Protein kinase CK2 triggers cytosolic zinc signaling pathways by phosphorylation of zinc channel ZIP7.

Authors:  Kathryn M Taylor; Stephen Hiscox; Robert I Nicholson; Christer Hogstrand; Peter Kille
Journal:  Sci Signal       Date:  2012-02-07       Impact factor: 8.192

Review 2.  NF-kappaB in carcinoma therapy and prevention.

Authors:  Matthew Brown; Jonah Cohen; Pattatheyil Arun; Zhong Chen; Carter Van Waes
Journal:  Expert Opin Ther Targets       Date:  2008-09       Impact factor: 6.902

3.  Nanoencapsulated anti-CK2 small molecule drug or siRNA specifically targets malignant cancer but not benign cells.

Authors:  Janeen H Trembley; Gretchen M Unger; Vicci L Korman; Diane K Tobolt; Zygmunt Kazimierczuk; Lorenzo A Pinna; Betsy T Kren; Khalil Ahmed
Journal:  Cancer Lett       Date:  2011-10-12       Impact factor: 8.679

4.  Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton.

Authors:  A A Kramerov; A G Golub; V G Bdzhola; S M Yarmoluk; K Ahmed; M Bretner; A V Ljubimov
Journal:  Mol Cell Biochem       Date:  2010-12-02       Impact factor: 3.396

5.  Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation.

Authors:  Janeen H Trembley; Gretchen M Unger; Omar Cespedes Gomez; J Abedin; Vicci L Korman; Rachel I Vogel; Gloria Niehans; Betsy T Kren; Khalil Ahmed
Journal:  Mol Cell Pharmacol       Date:  2014

6.  Co-expressions of casein kinase 2 (CK2) subunits restore the down-regulation of tubulin levels and disruption of microtubule structures caused by PrP mutants.

Authors:  Zhao-Yun Wang; Qi Shi; Shao-Bin Wang; Chan Tian; Ying Xu; Yan Guo; Cao Chen; Jin Zhang; Xiao-Ping Dong
Journal:  J Mol Neurosci       Date:  2012-07-01       Impact factor: 3.444

Review 7.  Protein kinase CK2 in health and disease: CK2 and its role in Wnt and NF-kappaB signaling: linking development and cancer.

Authors:  I Dominguez; G E Sonenshein; D C Seldin
Journal:  Cell Mol Life Sci       Date:  2009-06       Impact factor: 9.261

8.  Inhibition of protein kinase CK2 suppresses angiogenesis and hematopoietic stem cell recruitment to retinal neovascularization sites.

Authors:  A A Kramerov; M Saghizadeh; S Caballero; L C Shaw; S Li Calzi; M Bretner; M Montenarh; L A Pinna; M B Grant; A V Ljubimov
Journal:  Mol Cell Biochem       Date:  2008-07-09       Impact factor: 3.396

9.  Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2.

Authors:  Christopher C Williams; Aninda Basu; Abeer El-Gharbawy; Latonya M Carrier; Carolyn L Smith; Brian G Rowan
Journal:  BMC Biochem       Date:  2009-12-31       Impact factor: 4.059

10.  Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis.

Authors:  N Miyoshi; H Ishii; K Mimori; Y Takatsuno; H Kim; H Hirose; M Sekimoto; Y Doki; M Mori
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.